Odonate Therapeutics
Odonate, Inc., has no significant operations. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
Odonate Therapeutics (ODTC) - Net Assets
Latest net assets as of December 2022: $100.85 Million USD
Based on the latest financial reports, Odonate Therapeutics (ODTC) has net assets worth $100.85 Million USD as of December 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($103.73 Million) and total liabilities ($2.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $100.85 Million |
| % of Total Assets | 97.22% |
| Annual Growth Rate | 136.36% |
| 5-Year Change | -33.38% |
| 10-Year Change | N/A |
| Growth Volatility | 2788.37 |
Odonate Therapeutics - Net Assets Trend (2015–2023)
This chart illustrates how Odonate Therapeutics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Odonate Therapeutics (2015–2023)
The table below shows the annual net assets of Odonate Therapeutics from 2015 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $108.12 Million | +7.21% |
| 2022-12-31 | $100.85 Million | +70.17% |
| 2021-12-31 | $59.26 Million | -56.47% |
| 2020-12-31 | $136.15 Million | -16.12% |
| 2019-12-31 | $162.30 Million | +30.88% |
| 2018-12-31 | $124.00 Million | -36.73% |
| 2017-12-31 | $195.98 Million | +8484.41% |
| 2016-12-31 | $2.28 Million | +1956.76% |
| 2015-12-31 | $111.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Odonate Therapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38101400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $226.00K | 0.21% |
| Other Components | $492.37 Million | 455.39% |
| Total Equity | $108.12 Million | 100.00% |
Odonate Therapeutics Competitors by Market Cap
The table below lists competitors of Odonate Therapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GUANGDONG KANG.CO.LTD YC1
F:E9Q
|
$7.83 Million |
|
NKGen Biotech, Inc. Common Stock
PINK:NKGN
|
$7.84 Million |
|
CT AUTOMOTIVE GROUP -005
F:X7X
|
$7.84 Million |
|
Boldt S.A
BA:BOLT
|
$7.84 Million |
|
Keystone Reit Ltd
TA:KSTN
|
$7.83 Million |
|
Nico Resources Ltd
AU:NC1
|
$7.83 Million |
|
Energy Plug Technologies Corp
OTCQB:PLGGF
|
$7.83 Million |
|
System1 Inc
NYSE:SST
|
$7.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Odonate Therapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 100,849,000 to 108,121,000, a change of 7,272,000 (7.2%).
- Net income of 7,325,000 contributed positively to equity growth.
- Share repurchases of 196,000 reduced equity.
- Other comprehensive income increased equity by 143,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.33 Million | +6.77% |
| Share Repurchases | $196.00K | -0.18% |
| Other Comprehensive Income | $143.00K | +0.13% |
| Total Change | $- | 7.21% |
Book Value vs Market Value Analysis
This analysis compares Odonate Therapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 497.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 470.06x to 497.71x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $106.37 | $50000.00 | x |
| 2016-12-31 | $2187.75 | $50000.00 | x |
| 2017-12-31 | $368837.87 | $50000.00 | x |
| 2018-12-31 | $135177.80 | $50000.00 | x |
| 2019-12-31 | $156666.28 | $50000.00 | x |
| 2020-12-31 | $110475.92 | $50000.00 | x |
| 2021-12-31 | $42415.96 | $50000.00 | x |
| 2022-12-31 | $92335.65 | $50000.00 | x |
| 2023-12-31 | $100.46 | $50000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Odonate Therapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.77%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.02x
- Recent ROE (6.77%) is above the historical average (-65.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -142.34% | 0.00% | 0.00x | 1.26x | $-169.10K |
| 2016 | -135.13% | 0.00% | 0.00x | 1.26x | $-3.31 Million |
| 2017 | -16.71% | 0.00% | 0.00x | 1.04x | $-52.34 Million |
| 2018 | -71.74% | 0.00% | 0.00x | 1.15x | $-101.36 Million |
| 2019 | -68.90% | 0.00% | 0.00x | 1.16x | $-128.06 Million |
| 2020 | -92.81% | 0.00% | 0.00x | 1.23x | $-139.96 Million |
| 2021 | -115.27% | 0.00% | 0.00x | 1.33x | $-74.24 Million |
| 2022 | 42.58% | 0.00% | 0.00x | 1.03x | $32.86 Million |
| 2023 | 6.77% | 0.00% | 0.00x | 1.02x | $-3.49 Million |
Industry Comparison
This section compares Odonate Therapeutics's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Odonate Therapeutics (ODTC) | $100.85 Million | -142.34% | 0.03x | $7.83 Million |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |